NTGN News and Press, Neon Therapeutics Inc. From 12/11/19

Are Any Of These Penny Stocks On Your Watch List This Month? This week we saw something pivotal in the U.S. economy that could set the tone for 2020. Wednesday saw Federal Reserve Chairman Jerome Powell said the central bank’s attempt to ease the financial markets was working. What ...

Neon Therapeutics ( NTGN -7.1% ) extends yesterday's sharp losses after H.C. Wainwright piles on with a fresh downgrade to Neutral from Buy, citing the company's restructuring and strategic shift. More news on: Neon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, ...

Neon Therapeutics (NASDAQ: NTGN ) is down 3% to its all-time low following a cut to Underweight by Morgan Stanley, from Overweight. More news on: Neon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Nano cap Neon Therapeutics (NASDAQ: NTGN ) jumps  19%  after hours in response to its announced restructuring aimed at sharpening its focus on developing its novel neoantigen-based T cell programs. More news on: Neon Therapeutics, Inc., Healthcare stocks news, Stocks on the mov...

Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors Corporate restructuring effected to focus resources while exploring strategic options CAMBRIDGE, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, I...

Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Buy rating and $110 (21% upside) price target at BofA Merrill Lynch. More news on: Alnylam Pharmaceuticals, Inc., Arena Pharmaceuticals, Inc., National Vision Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Neon Therapeutics (NASDAQ: NTGN ): Q3 GAAP EPS of -$0.68 misses by $0.01 . More news on: Neon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the third quarter ended September 30, 2019 and provided a business up...

Updated Results from NT-001 Trial of NEO-PV-01 Demonstrate Prolonged Progression-Free and Overall Survival vs. Historical Benchmark Data Advanced Process Development Supports Clinical Trial Application to be Filed in Europe by End of Year for T cell Therapy Candidate NEO-PTC-01 CAM...

Gainers : Pier 1 Imports (NYSE: PIR ) +28% . Endo International (NASDAQ: ENDP ) +24% . Autolus Therapeutics (NASDAQ: AUTL ) +25% . Microbot Medical (NASDAQ: MBOT ) +24% . Hovnanian Enterprises (NYSE: HOV ) +20% . Lannett Company (NYSE: LCI ) +20% . DocuSign (NASDAQ: DOCU ) +19% . Su...